menu
    • menu
    [{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Inotrem","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Nangibotide","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Roche Diagnostics GmbH \/ Roche Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Roche Diagnostics GmbH \/ Roche Diagnostics"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PDL1\/PD1","graph1":"Oncology","graph2":"Approved","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Roche Diagnostics GmbH \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Roche Diagnostics GmbH \/ Merck"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Roche Diagnostics GmbH \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Roche Diagnostics GmbH \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Approved","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Roche Diagnostics GmbH \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Roche Diagnostics GmbH \/ AstraZeneca"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Roche Diagnostics GmbH \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Roche Diagnostics GmbH \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Roche Diagnostics GmbH

    Menu

    Roche Diagnostics GmbH

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Roche Diagnostics GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Roche Diagnostics GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crovalimab

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Roche Announces Positive Data from Global Phase III Programme for Crovalimab In PNH, A Rare Life-Threatening B...

                            Details : RG6107 (crovalimab) is an investigational, novel anti-C5 recycling monoclonal antibody designed to block the complement system which plays a vital part of the innate immune system that acts as the body’s first line of defence against infection.

                            Brand Name : RG6107

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 07, 2023

                            Lead Product(s) : Crovalimab

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Roche Diagnostics GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Roche Diagnostics GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deruxtecan

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Roche Receives FDA Approval For First Companion Diagnostic To Identify Patients With HER2 Low Metastatic Breas...

                            Details : PATHWAY anti-HER2 test is only FDA approved companion diagnostic indicated as an aid in assessment of HER2 low status in metastatic breast cancer patients, who may consider ENHERTU (fam-trastuzumab deruxtecan-nxki) as a treatment option based on results ...

                            Brand Name : Enhertu

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 04, 2022

                            Lead Product(s) : Deruxtecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Roche Diagnostics GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Roche Diagnostics GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cemiplimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Roche's VENTANA PD-L1 (SP263) Assay Receives CE IVD Approval To Identify Patients With Locally Advanced And Me...

                            Details : The VENTANA PD-L1 (SP263) Assay as a companion diagnostic helps determine which patients with non-small cell lung cancer may be eligible for treatment with Libtayo monotherapy based on the results of the Phase III EMPOWER-Lung 1 study.

                            Brand Name : Libtayo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 09, 2022

                            Lead Product(s) : Cemiplimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Roche Diagnostics GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Roche Diagnostics GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pembrolizumab,Lenvatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Roche Receives FDA Approval for VENTANA MMR RxDx Panel to Identify dMMR Solid Tumour Patients and pMMR Endomet...

                            Details : The VENTANA MMR RxDx Panel is the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (dMMR), and who may be eligible for KEYTRUDA® (pembrolizumab).

                            Brand Name : Keytruda

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 11, 2022

                            Lead Product(s) : Pembrolizumab,Lenvatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Roche Diagnostics GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Roche Diagnostics GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nangibotide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Recipient : Inotrem

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Inotrem Secures Strategic Licensing Agreement for a Companion Diagnostics Test in Septic Shock

                            Details : Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 21, 2020

                            Lead Product(s) : Nangibotide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Recipient : Inotrem

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth